Nuclear Imaging for Subtype Diagnosis of Primary Aldosteronism

Summary

This study is to evaluate the accuracy of a novel radiopharmaceutical tracer, para-chloro-2-\[18F\]fluoroethyl etomidate (CETO), used with positron emission tomography (PET) and computed tomography (CT), as a way to subtype unilateral vs. bilateral forms of Primary Aldosteronism, compared to AVS as a reference gold standard.

Timeline

Start

2023-01-01

Primary completion

2026-06-30

Completion

2026-06-30

Drugs

Indications